Seeking Alpha update - Biocryst remains overweight at Piper Sandler, PT $24 | BCRX Message Board Posts


BioCryst Pharmaceuticals Inc.

  BCRX website

BCRX   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  12820 of 12828  at  4/12/2022 10:58:32 AM  by

moegrabbedmythumb

The following message was updated on 4/12/2022 10:59:31 AM.

Seeking Alpha update - Biocryst remains overweight at Piper Sandler, PT $24

  

10:47 AM | BioCryst Pharmaceuticals, Inc. (BCRX) | By: Jonathan Block, SA News Editor

  • Piper Sandler is reiterating its overweight rating for BioCryst (NASDAQ:BCRX) arguing that weakness following Friday's announcement of a trial enrollment pause for BCX9930 provides a buying opportunity.
  • The firm has a $24 price target (~121% upside based on Monday's close).
  • Analyst Christopher Raymond wrote, "we think a dearth of information has led to a number of misinterpretations...we wonder if enrollment simply gets back on track (with added precautions)."
  • Raymond added that he doesn't think the pause is the result of a problem with the drug itself given that BCX9930, an oral factor D inhibitor, is a complement blocking therapy that reduces hemolysis.
 


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 2  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board




Financial Market Data provided by
.
Loading...